UBE2S and cancer: Previous works have illustrated that distinct UBE2S elevation is harbored in multiple human cancers, and aberrant UBE2S expression is responsible for carcinogenicity, cell cycle disruption, drug resistance, and attenuation of ischemia-reperfusion injury (IRI) [9, 25–27].